JAMA Dermatology

<jats:sec id="ab-doi230041-4"><jats:title>Importance</jats:title><jats:p>Melanoma treatment has evolved during the past decade with the adoption of adjuvant and palliative immunotherapy and targeted therapies, with an unclear impact on health care costs and outcomes in routine practice.</jats:p></jats:sec><jats:sec id="ab-doi230041-5"><jats:title>Objective</jats:title><jats:p>To examine changes in health care costs, overall survival (OS), and time toxicity associated with primary treatment of melanoma.</jats:p></jats:sec><jats:sec id="ab-doi230041-6"><jats:title>Design, Setting, and Participants</jats:title><jats:p>This cohort study assessed a longitudinal, propensity score (PS)–matched, retrospective cohort of residents of Ontario, Canada, aged 20 years or older with stages II to IV cutaneous melanoma identified from the Ontario Cancer Registry from January 1, 2018, to March 31, 2019. A historical comparison cohort was identified from a population-based sample of invasive melanoma cases diagnosed from the Ontario Cancer Registry from January 1, 2007, to December 31, 2012. Data analysis was performed from October 17, 2022, to March 13, 2023.</jats:p></jats:sec><jats:sec id="ab-doi230041-7"><jats:title>Exposures</jats:title><jats:p>Era of melanoma diagnosis (2007-2012 vs 2018-2019).</jats:p></jats:sec><jats:sec id="ab-doi230041-8"><jats:title>Main Outcomes and Measures</jats:title><jats:p>The primary outcomes were mean per-capita health care and systemic therapy costs (Canadian dollars) during the first year after melanoma diagnosis, time toxicity (days with physical health care contact) within 1 year of initial treatment, and OS. Standardized differences were used to compare costs and time toxicity. Kaplan-Meier methods and Cox proportional hazards regression were used to compare OS among PS-matched cohorts.</jats:p></jats:sec><jats:sec id="ab-doi230041-9"><jats:title>Results</jats:title><jats:p>A PS-matched cohort of 731 patients (mean [SD] age, 67.9 [14.8] years; 437 [59.8%] male) with melanoma from 2018 to 2019 and 731 patients (mean [SD] age, 67.9 [14.4] years; 440 [60.2%] male) from 2007 to 2012 were evaluated. The 2018 to 2019 patients had greater mean (SD) health care (including systemic therapy) costs compared with the 2007 to 2012 patients ($47 886 [$55 176] vs $33 347 [$31 576]), specifically for stage III ($67 108 [$57 226] vs $46 511 [$30 622]) and stage IV disease ($117 450 [$79 272] vs $47 739 [$37 652]). Mean (SD) systemic therapy costs were greater among 2018 to 2019 patients: stage II ($40 823 [$40 621] vs $10 309 [$12 176]), III ($55 699 [$41 181] vs $9764 [$12 771]), and IV disease ($79 358 [$50 442] vs $9318 [$14 986]). Overall survival was greater for the 2018 to 2019 cohort compared with the 2007 to 2012 cohort (3-year OS: 74.2% [95% CI, 70.8%-77.2%] vs 65.8% [95% CI, 62.2%-69.1%], hazard ratio, 0.72 [95% CI, 0.61-0.85]; <jats:italic>P</jats:italic> &amp;amp;lt; .001). Time toxicity was similar between eras. Patients with stage IV disease spent more than 1 day per week (&amp;amp;gt;52 days) with physical contact with the health care system by 2018 to 2019 (mean [SD], 58.7 [43.8] vs 44.2 [26.5] days; standardized difference, 0.40; <jats:italic>P</jats:italic> = .20).</jats:p></jats:sec><jats:sec id="ab-doi230041-10"><jats:title>Conclusions and Relevance</jats:title><jats:p>This cohort study found greater health care costs in the treatment of stages II to IV melanoma and substantial time toxicity for patients with stage IV disease, with improvements in OS associated with the adoption of immunotherapy and targeted therapies. These health system–wide data highlight the trade-off with adoption of new therapies, for which there is a greater economic burden to the health care system and time burden to patients but an associated improvement in survival.</jats:p></jats:sec>

Projections of the cost of cancer care in the United States: 2010-2020.

J Natl Cancer Inst

The economic burden of cancer care in Canada: a population-based cost study.

CMAJ Open

Cancer statistics, 2021.

CA Cancer J Clin

Projected estimates of cancer in Canada in 2020.

CMAJ

NCCN Guidelines® Insights: melanoma: cutaneous, version 2.2021.

J Natl Compr Canc Netw

Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.

Curr Oncol

Improved survival with ipilimumab in patients with metastatic melanoma.

N Engl J Med

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma.

Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.

Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.

J Immunother Cancer

Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.

J Med Econ

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Lancet

Systemic therapy for melanoma: ASCO guideline.

J Clin Oncol

Completion dissection or observation for sentinel-node metastasis in melanoma.

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.

Lancet Oncol

The time toxicity of cancer treatment.

Caregiver burden #419.

J Palliat Med

What is value in health care?

Diagnostic error, uncertainty, and overdiagnosis in melanoma.

Pathology

Disparities in diagnosis of advanced melanoma: a population-based cohort study.

Identifying increased risk of readmission and in-hospital mortality using hospital administrative data.

Med Care

The generation of two specific cancer costing algorithms using Ontario administrative databases.

Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study.

Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.

Pharm Stat

Comparative healthcare costs in patients with metastatic melanoma in the USA.

Melanoma Res

Cost and utilization of immunotherapy and targeted therapy for melanoma: cross-sectional analysis in the Medicare population, 2013 and 2015.

J Am Acad Dermatol

Healthcare costs of metastatic cutaneous melanoma in the era of immunotherapeutic and targeted drugs.

Cancers (Basel)

Health care resource utilization and associated costs among metastatic cutaneous melanoma patients treated with ipilimumab (INTUITION study).

Oncologist

Direct costs associated with adverse events of systemic therapies for advanced melanoma: systematic literature review.

Medicine (Baltimore)

Economic burden of adverse events associated with immunotherapy and targeted therapy for metastatic melanoma in the elderly.

Am Health Drug Benefits

Economic burden of toxicities associated with treating metastatic melanoma in eight countries.

Eur J Health Econ

Economic evaluation of talimogene laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy in patients with advanced unresectable melanoma.

JAMA Dermatol

Cost-effectiveness of second-line ipilimumab for metastatic melanoma: a real-world population-based cohort study of resource utilization.

Cancer Med

Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.

Cost-effectiveness of drug treatments for advanced melanoma: a systematic literature review.

Pharmacoeconomics

Economic evaluation of systemic treatments for advanced melanoma: a systematic review.

Value Health

Determination of the impact of melanoma surgical timing on survival using the National Cancer Database.

Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.

Br J Cancer

A population-based study of survival impact of new targeted and immune-based therapies for metastatic or unresectable melanoma.

Clin Oncol (R Coll Radiol)

Current landscape of immunotherapy in breast cancer: a review.

JAMA Oncol

First-line immunotherapy for non–small-cell lung cancer.

Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results.

Pembrolizumab in microsatellite-instability–high advanced colorectal cancer.

Melanoma treatment has evolved during the past decade with the adoption of adjuvant and palliative immunotherapy and targeted therapies, with an unclear impact on health care costs and outcomes in routine practice.
To examine changes in health care costs, overall survival (OS), and time toxicity associated with primary treatment of melanoma.
This cohort study assessed a longitudinal, propensity score (PS)-matched, retrospective cohort of residents of Ontario, Canada, aged 20 years or older with stages II to IV cutaneous melanoma identified from the Ontario Cancer Registry from January 1, 2018, to March 31, 2019. A historical comparison cohort was identified from a population-based sample of invasive melanoma cases diagnosed from the Ontario Cancer Registry from January 1, 2007, to December 31, 2012. Data analysis was performed from October 17, 2022, to March 13, 2023.
Era of melanoma diagnosis (2007-2012 vs 2018-2019).
The primary outcomes were mean per-capita health care and systemic therapy costs (Canadian dollars) during the first year after melanoma diagnosis, time toxicity (days with physical health care contact) within 1 year of initial treatment, and OS. Standardized differences were used to compare costs and time toxicity. Kaplan-Meier methods and Cox proportional hazards regression were used to compare OS among PS-matched cohorts.
A PS-matched cohort of 731 patients (mean [SD] age, 67.9 [14.8] years; 437 [59.8%] male) with melanoma from 2018 to 2019 and 731 patients (mean [SD] age, 67.9 [14.4] years; 440 [60.2%] male) from 2007 to 2012 were evaluated. The 2018 to 2019 patients had greater mean (SD) health care (including systemic therapy) costs compared with the 2007 to 2012 patients ($47 886 [$55 176] vs $33 347 [$31 576]), specifically for stage III ($67 108 [$57 226] vs $46 511 [$30 622]) and stage IV disease ($117 450 [$79 272] vs $47 739 [$37 652]). Mean (SD) systemic therapy costs were greater among 2018 to 2019 patients: stage II ($40 823 [$40 621] vs $10 309 [$12 176]), III ($55 699 [$41 181] vs $9764 [$12 771]), and IV disease ($79 358 [$50 442] vs $9318 [$14 986]). Overall survival was greater for the 2018 to 2019 cohort compared with the 2007 to 2012 cohort (3-year OS: 74.2% [95% CI, 70.8%-77.2%] vs 65.8% [95% CI, 62.2%-69.1%], hazard ratio, 0.72 [95% CI, 0.61-0.85]; P < .001). Time toxicity was similar between eras. Patients with stage IV disease spent more than 1 day per week (>52 days) with physical contact with the health care system by 2018 to 2019 (mean [SD], 58.7 [43.8] vs 44.2 [26.5] days; standardized difference, 0.40; P = .20).
This cohort study found greater health care costs in the treatment of stages II to IV melanoma and substantial time toxicity for patients with stage IV disease, with improvements in OS associated with the adoption of immunotherapy and targeted therapies. These health system-wide data highlight the trade-off with adoption of new therapies, for which there is a greater economic burden to the health care system and time burden to patients but an associated improvement in survival.

Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.

Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma

Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma

Clinical Summary

What was studied

Key findings

Study limitations

Clinical implications

Related Questions